Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

The Largest Registry on the ACURATE neo Valve

Transcatheter aortic valve replacement (TAVR) using the ACURATE neo device depends, largely, on correct patient selection and appropriate oversizing. The individual anatomy of each patient, namely periannular and aortic root calcification, must be taken into account.

The ACURATE neo valve (Symetis/Boston, Ecublens, Switzerland) is a new-generation self-expanding valve characterized by a stent design shaped as an X and a unique release mechanism. This work analyzed technical and anatomical predictors for proper implantation of this device.

A total of 500 patients who underwent TAVR with the ACURATE neo valve were stratified according to landing zone calcification level (mild, moderate, or severe). Predictors of moderate or greater paravalvular leak and need for permanent pacemaker implantation were assessed.


Read also: Renal Impairment: How Does It Affect Angioplasty and Surgery?


Post-procedural moderate or greater paravalvular leak was more frequent with increasing device landing zone calcification (mild, 0.8% vs. moderate, 5.0% vs. severe, 13.0%; p < 0.001), while the need for permanent pacemaker implantation was independent of calcification.

The greater the periannular calcification (p < 0.001), the lesser the oversizing (p = 0.014), the higher the presence of annular plaque protrusions (p = 0.025), the greater the movement of the release system after full valve deployment (p = 0.02), and the higher the sinotubular junction height (p = 0.04). There was a higher rate of paravalvular insufficiency.


Read also: DEFENSE-PFO: High Risk PFO Closure Reduces Combined Events and Stroke Risk.


As regards predictors of permanent pacemaker implantation, there were no surprises compared with other studies or devices: pre-existing right bundle branch block and more oversizing.

Conclusion

Procedural success using the ACURATE neo device depends on appropriate oversizing and consideration of individual anatomy, mainly periannular and aortic root calcium distribution. To sum up, success depends on correct patient selection.

Original title: The ACURATE Neo Transcatheter Heart Valve. A Comprehensive Analysis of Predictors of Procedural Outcome.

Reference: Won-Keun Kim et al. J Am Coll Cardiol Intv 2018. Online before print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Su opinión nos interesa. Puede dejar su comentario, reflexión, pregunta o lo que desee aquí abajo. Será más que bienvenido.

More articles by this author

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

TAVI in TAVI: Clinical and Hemodynamic Outcomes According to the Type of Prosthesis Used in TAVI-in-TAVI

With the expansion of TAVI to younger and lower surgical risk patients, bioprosthetic valve degeneration and the need for repeat interventions are expected to...

Percutaneous Closure of Patent Foramen Ovale in Patients Over 60 Years Old With Cryptogenic Stroke: A Safe and Effective Strategy?

Cryptogenic stroke accounts for up to one-third of all ischemic strokes and remains strongly associated with the presence of a patent foramen ovale (PFO),...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...